12 July 2018 - Positive outcome of joint reimbursement negotiations on Spinraza

Beneluxa Initiative partners Belgium and the Netherlands successfully negotiated the reimbursement of Spinraza

Belgium and the Netherlands have reached an agreement on the pricing of Spinraza, a drug for Spinal Muscular Atrophy (SMA). Spinraza will be reimbursed for specific groups of patients in both countries.

The aim of the Beneluxa Initiative is to enhance the access of patients to high quality and affordable treatment. The agreement on Spinraza is the first positive outcome of a joint negotiation of the Beneluxa Initiative. As a result of negotiations, which started in February of this year, Spinraza will be reimbursed in both countries under similar conditions. The joint process consisted of a joint Health Technology Assessment, followed by a joint price negotiation. 

Although previous pilots have proven that joint negotiations can be successful, this particular case is a great achievement that benefits patients in both countries. 
Ireland has recently joined the Beneluxa Initiave too. With several pilots ongoing, the aim is to expand future negotiations with other Beneluxa partners and to enhance efficiency by streamlining reimbursement processes in different countries.

Bruno Bruins: ‘First and foremost, the positive outcome is wonderful news for the young SMA patients and their families, both in the Netherlands and Belgium. It is also a very clear and promising example of the benefits of working together on price negotiations and pharmaceutical policy. Biogen’s willingness to engage in a joint process and discover the benefits of gaining swift access in several markets at the same time is a positive development. Therefore I hope more companies will follow this example.’

Maggie de Block: ‘I am delighted to be able to make this orphan drug available to our SMA patients, barely one year after it received a marketing authorization. There was no treatment at all for these patients, but that is now changing. This means a giant step forward for these people and their families. At the same time, I am very proud of how we have tackled this. Today, we demonstrate that countries can jointly negotiate the reimbursement of orphan drugs to the benefit of their patients. This is a very important signal for everyone involved in Beneluxa and an extra motivation to further develop this international cooperation.’

For more specific details on the reimbursement of Spinraza in Belgium and the Netherlands, read the specific press releases:
Link Belgium
Link The Netherlands

Last update: 12 July 2018


22 June 2018 -  Ireland joins Beneluxa initiative

Ireland joins

Today, the Irish Minister for Health, Simon Harris signed an Agreement with his colleagues from Belgium, The Netherlands, Luxembourg and Austria to join the Beneluxa Initiative on Pharmaceutical Policy. The ceremony took place during the Employment, Social Policy, Health and Consumer Affairs Council (EPSCO) in Luxembourg. Ireland is the fifth country to join the collaborative alliance on pharmaceutical policy.

Minister Harris stated: “I am pleased that my Ministerial colleagues from Austria, Belgium, The Netherlands and Luxembourg have enabled Ireland to join this exciting, international collaboration on drug pricing and supply.  I want the newest and most innovative medicines to be available in a timely manner to all our citizens. This collaboration will assist us in doing just that by ensuring that medicines can be sourced at a price that is affordable and sustainable in the context of the ever competing demands for resources rights across our health service”. 
The BeNeLuxA Ministers responsible for pharmaceutical policy welcomed Ireland joining and participating in the collaboration. 

Dutch minister Bruno Bruins for Medical care said: “Ireland is a great addition to the Beneluxa family. All five countries face similar issues regarding  access and affordability to new and innovative medicines. By joining forces we improve our mutual position in price negotiations towards the pharmaceutical industry and we have a stronger voice at European level. In this way we can ensure that our patients can count on access to affordable, innovative medicines in the long term”.

Belgian minister Maggie De Block of Social Affairs and Public Health said: "Four years ago, each country still worked on its own. Today,  we are five countries joining forces, our objective being to offer the best care possible, as soon as possible and in a sustainable way to  all our patients. I hope that other European countries will join us soon. Because the more patients we represent, the more our voice will be heard when discussing high-cost innovative medicines".
Luxembourg minister of Health Lydia Mutsch said: “We believe that information sharing and collaboration between countries will benefit policy initiatives on pricing and reimbursement of medicines. By working closely together, we can better negotiate medicine prices with the industry and request more transparency on the cost build-up of pharmaceutical products. Our aim is to ensure patients’ fair and sustainable access to essential medicines.

Beneluxa achievements 

In 2015 the Beneluxa initiative was initiated aiming for sustainable access to, and appropriate use of, medicines in the participating countries. Together, the countries want to enhance patients’ access to high quality and affordable pharmaceutical treatments. The cooperation is not limited to joint pricing negotiations. The coalition also works together closely on a horizon scanning, to explore which innovative – often extremely expensive – medicines are expected to reach the market in the near future. In addition, the Beneluxa partners conduct joint health technology assessments and share data and policies. The collaboration recently introduced the international horizon scanning initiative (IHSI), that goes beyond the current coalition of countries. Its goal is to build a permanent horizon scanning system that can support countries and institutions in policy planning and their decision making regarding the reimbursement of new pharmaceuticals. A wide group of countries is currently invested in developing the IHSI further.
More info on the Beneluxa initiative can be found on

Last update: 22 June 2018

24 May 2018 - Steering Commitee Meeting

On the 24th of May 2018, the Steering Committee of the Beneluxa Initiative met in Brussels. On the 25th of  May 2018, the Beneluxa General Assembly took place. A representative of Ireland, at the time in process of joining the Initiative, participated in the Steering Committee meeting.
The following topics were discussed:

1. updates on the on the Initiative’s four Domain Task Forces:

2. Alternative business models to develop medicines (such as the Fair Medicines Initiative)

3. Austria’s planned activities related to pharmaceutical policy under the upcoming EU Presidency

4. Developments concerning the reimbursement of pharmaceuticals in Europe

5. The Beneluxa Initiative has opened a twitter account to announce news and new content on the website. The Beneluxa Initiative twitter can be found at

18 January 2018 - Steering Commitee Meeting

The Steering Committee of the Beneluxa initiative met in Luxembourg on 18 January 2018.

Experiences with joint HTA reports and joint negotiations were assessed, and the planned activities for 2018 in the areas of HTA and pricing and reimbursement were discussed. Topics included a discussion of moving ahead with collaboration in the areas of Horizon Scanning and patient registries.


28 November 2017 - Orientation Meeting on Patient Registries

Policy makers and national patient registry experts from Beneluxa countries, Hungary and the United Kingdom met in Vienna on 28 November 2017 to explore a possible collaboration in the field of patient registries in order to increase efficiency, and enhance evidence generation and information sharing. 

The meeting aimed to identify the challenges and prerequisites for collaboration in the field of patient registries, and ways to move forward. As a supportive exercise, results of a preliminary mapping of patient registries in the member countries of the Beneluxa initiative were presented. As different types of registries exist, key learnings included the need for a clear definition of patient registries and scope in order to determine which type of registry would be appropriate for a potential pilot in the near future. Furthermore, technical and political challenges of a joint registry (e.g. interoperability of datasets, legal framework/collaboration agreements, as well as how necessary information can be collected) were identified. 

The Beneluxa partners will further explore a collaboration in the field of patient registries. 


11 November 2017

Information on the first results of actual joint HTA procedures are available here.


6 September 2017 - Website of the Beneluxa collaboration launched

The competent authorities of Belgium, the Netherlands, Luxembourg, and Austria have committed to cooperate in order to contribute towards the sustainable access to medicines in their countries.

Further information on the Beneluxa cooperation can be found on this website, which was launched on September 6, 2017.


27 June 2017 - Meeting on Joint Horizon Scanning

A meeting was organised in Brussels on 27 June 2017 to explore options for potential collaboration between authorities on Horizon Scanning - even beyond the Beneluxa countries.